Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (11725)	4/23/2003 6:29:58 PM
From: BW	Respond to of 48461

ARIA is a tough one, macd is positive but Williams and stoch are indicating oversold. it did make a nice base with increasing volume this month. total mixed signals to me...hard to read it. does look like its got a good chance though.. FONR is looking good, I bought back in in the mid 80's

To: Bucky Katt who wrote (11725)	4/23/2003 9:38:57 PM
From: ALTERN8	Respond to of 48461

AKAM, finally!

To: Bucky Katt who wrote (11725)	4/24/2003 9:08:34 AM
From: Findit	Respond to of 48461

LSBC up 47% on news - Large Scale Biology Corporation to Initiate Field Production of Recombinant Aprotinin VACAVILLE, Calif., Apr 24, 2003 (BUSINESS WIRE) -- Large Scale Biology Corporation (Nasdaq:LSBC) will initiate field production this year of recombinant aprotinin, a protease inhibitor used to minimize bleeding and decrease inflammation during cardiopulmonary bypass surgery. Aprotinin was identified as a primary product target for LSBC by President and CEO Kevin J. Ryan in a public conference call earlier this week. The growing market for this drug at current supply is estimated to be up to $300 million. Field production at two sites with different growing seasons is expected to demonstrate LSBC's proprietary process for the cost-effective, year-round supply of aprotinin to final formulators in medical, manufacturing and research markets. Using its proprietary GENEWARE(R) plant-based biomanufacturing system, LSBC has produced pilot quantities of recombinant aprotinin without the safety and supply concerns associated with currently available product obtained by extraction from bovine lungs. The commercial scale-up program for aprotinin is the responsibility of LSBC's biomanufacturing division in Owensboro, Kentucky. LSBC's aprotinin program is part of a corporate strategy to produce specialty biologics for revenue while demonstrating the robust properties of GENEWARE technology for producing safe biopharmaceuticals for humans in plants. LSBC's technology provides a method for producing biopharmaceuticals free of human or animal pathogens by using non-GMO, non-food plants as a production host. About Large Scale Biology Corporation Large Scale Biology uses its biomanufacturing, functional genomics and proteomics technologies to develop and manufacture drugs and vaccines for effective treatment of disease. Corporate offices, the Genomics Division and Biopharmaceutical Development laboratories are headquartered in Vacaville, California; the Company's Proteomics Division is located in Germantown, Maryland; and the Company's commercial-scale Biomanufacturing facility is located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com. This release contains forward-looking statements about an application of LSBC's technologies and the potential size of the market for one of our products. These forward-looking statements involve risks, uncertainties and situations that may cause our actual results to differ materially from those implied by these statements, including the ability of our collaborators to generate demand for products we make for them, the effectiveness of our and our collaborators' technologies to produce specific therapeutic products and/or in a cost-effective manner, any difficulties or delays in obtaining regulatory approval to test and market such products, and the requirement of substantial funding for us to preserve our technology base and product pipeline. We cannot guarantee future results. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this release. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities and Exchange Commission, including our reports on Forms 10-K and 10-Q. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. LSBC(TM) is a trademark of Large Scale Biology Corporation. GENEWARE(R) is a registered trademark of Large Scale Biology Corporation. Large Scale Biology Corporation Daniel J. Moriarty, 707/446-5501 ext. 347 (VP, Corporate Affairs) dan.moriarty@lsbc.com Carol Higgins, 707/446-5501 ext. 308 (Corporate Affairs) businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2003 Business Wire. All rights reserved. NewsProvided by COMTEX, comtex.com

To: Bucky Katt who wrote (11725)	4/24/2003 10:09:52 AM
From: tsigprofit	Respond to of 48461

William, thanks for posting. I want to take a look at our list today. I own some FONR, but want to check out the others also. t